Non-Invasive Continuous Glucose Monitoring Wearable
Benchmarked against FDA-approved global brands and rejected three times over U.S. regulatory risk, the device was repositioned against the finger-prick glucometer and closed a term sheet at its second post-reframe meeting.
- Origin
- Joint initiative of an IIT biomedical engineering department and a hospital endocrinology unit
- Founded
- 2021
- Core Innovation
- Wrist-worn near-infrared spectroscopy device with a machine learning model trained on Indian patient data; Mean Absolute Relative Difference of 12.4% across 180-patient clinical testing. Target segment: Type 2 diabetics on oral medication requiring between-meal trend monitoring.
- Capital Outcome
- ₹8.40 Crore seed equity from a MedTech-focused venture fund with family office co-investment
Diagnostic findings at engagement
- The company's competitive positioning materials compared the device directly to internationally established continuous glucose monitoring brands with full FDA approval, inviting investor scrutiny on regulatory risk the company was not yet positioned to address.
- The stated regulatory plan was limited to a general intention to obtain CDSCO approval, with no defined device classification, predicate device identification, or submission timeline.
- The go-to-market model was direct-to-consumer, a structure that produces high customer acquisition cost and no prescription-driven adoption mechanism in the diabetic device category.
- Three prior venture pitches had each resulted in rejection, with all three citing United States FDA approval risk as the principal concern, despite the company's near-term commercial plan being limited to the Indian market.
- No clinical advisory board existed: a standard diligence expectation among MedTech-focused investors evaluating clinical credibility.
Service interventions applied
Competitive Positioning Correction
Removed international continuous glucose monitoring brands from the competitive landscape and repositioned the device against the finger-prick glucometer (the actual Indian market incumbent, with a comparable monthly cost structure of approximately ₹2,160), eliminating the unprompted FDA risk discussion that had recurred across prior investor meetings.
Regulatory Strategy
Defined the device's CDSCO classification as Class B Software as a Medical Device under the predicate category of glucose monitoring aids, and constructed an 18-month submission timeline, clarifying that United States regulatory approval was a Phase 2 international expansion consideration rather than a Phase 1 India launch requirement.
Go-to-Market Redesign
Replaced the direct-to-consumer channel with a B2B2C model routed through diabetologist clinical networks and existing diabetes management application platforms, reducing customer acquisition cost from an estimated ₹4,200 to ₹380 through prescription-driven adoption.
Clinical Advisory Board Formation
Facilitated recruitment of three key opinion leader endocrinologists from three distinct major Indian teaching hospitals as clinical advisors with nominal equity, materially changing the tenor of subsequent investor conversations by signalling established clinical credibility.
Financial Model Construction
Built a three-stream revenue model combining one-time hardware sale at an average selling price of ₹4,800, a monthly data platform subscription at ₹299, and anonymised data licensing to pharmaceutical companies for drug-device clinical trial support, projecting Year 3 revenue of ₹22 Crore with gross margins of 34%, 81%, and 92% across the three streams respectively.
Investor Preparation and Coaching
Conducted structured pitch rehearsals incorporating anticipated investor objections regarding regulatory comparison and CDSCO planning, ensuring both objections were pre-empted within the first three slides of subsequent pitches rather than arising reactively during investor questioning.
Position at engagement vs. position at close
Swipe the table sideways to compare.
| Dimension | At engagement | At close |
|---|---|---|
| Competitive Framing | Benchmarked against FDA-approved international brands | Benchmarked against finger-prick glucometer incumbent |
| Customer Acquisition Cost | Estimated ₹4,200 (direct-to-consumer) | Estimated ₹380 (prescription-driven, B2B2C) |
| Clinical Credibility | No clinical advisory board | Three key opinion leader endocrinologists engaged |
| Venture Outcome | Three rejections citing FDA risk | Term sheet at second meeting post-reframing |
| Capital Secured | ₹0 | ₹8.40 Crore |